Cargando…
Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder
OBJECTIVE: The purpose of this study was to review cases of neuromyelitis optica spectrum disorder (NMOSD) relapses and pseudorelapses to identify early features that differentiate between them at onset of symptoms. METHODS: This was a retrospective analysis of 74 hospitalizations of patients with N...
Autores principales: | Kessler, Remi A., Mealy, Maureen A., Levy, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966291/ https://www.ncbi.nlm.nih.gov/pubmed/27508210 http://dx.doi.org/10.1212/NXI.0000000000000269 |
Ejemplares similares
-
A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder
por: Mealy, Maureen A., et al.
Publicado: (2019) -
Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica
por: Levy, Michael, et al.
Publicado: (2014) -
B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
por: Levy, Michael, et al.
Publicado: (2021) -
Mortality in neuromyelitis optica is strongly associated with African ancestry
por: Mealy, Maureen A., et al.
Publicado: (2018) -
Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder
por: Chavarro, Velina S., et al.
Publicado: (2016)